Table 4—

Per cent of patients whose forced expiratory volume in one second (FEV1) (% change) or daytime symptom scores (DSS) (change) were not improved, but whose patient global evaluation (PG) or quality of life (QoL) was improved

Treatment groupPatients with FEV1 %#≤0Among patients with no improvement in FEV1Patients with DSS change≥0Among patients with no improvement in DSS
PG improved %QoL improved %PG improved %QoL improved %
Placebo203 (41.9)57.365.0175 (36.2)62.159.4
Montelukast193 (25.8)76.472.5193 (25.8)71.561.7
Beclomethasone54 (22.9)96.277.438 (16.2)94.457.9
  • Data are presented as n (%), unless otherwise stated

  • #: per cent change from baseline

  • : change from baseline